Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date

Eric R Chen,1 Peter K Kaiser2 1School of Medicine, Case Western Reserve University, Cleveland, OH, USA; 2Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USACorrespondence: Peter K KaiserCole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3-125, Cleveland, OH 44...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen ER, Kaiser PK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	neovascular age-related macular degeneration ranibizumab port delivery system vascular endothelial growth factor Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/60b76b3947b14542a819c4a9a24895dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60b76b3947b14542a819c4a9a24895dd
record_format	dspace
spelling	oai:doaj.org-article:60b76b3947b14542a819c4a9a24895dd2021-12-02T08:05:16ZTherapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date1177-5483https://doaj.org/article/60b76b3947b14542a819c4a9a24895dd2020-05-01T00:00:00Zhttps://www.dovepress.com/therapeutic-potential-of-the-ranibizumab-port-delivery-system-in-the-t-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Eric R Chen,1 Peter K Kaiser2 1School of Medicine, Case Western Reserve University, Cleveland, OH, USA; 2Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USACorrespondence: Peter K KaiserCole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3-125, Cleveland, OH 44195, USATel +1 (216) 444-6702Email kaiserp@ccf.orgAbstract: Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults worldwide. The advent of intravitreal neutralization of vascular endothelial growth factor (VEGF) has revolutionized the management of patients with neovascular AMD, but current anti-VEGF therapies carry a high threshold of patient burden. The ranibizumab port delivery system (PDS) is an implanted, refillable reservoir that continuously supplies the anti-VEGF medication ranibizumab directly into the vitreous, eliminating the need for frequent intravitreal injections. It has most recently been evaluated in the Phase II LADDER trial demonstrating the efficacy and safety of the PDS, with Phase III trials currently underway. This review presents both the promise and drawbacks of the PDS in the treatment of AMD from the current literature.Keywords: neovascular age-related macular degeneration, ranibizumab, port delivery system, vascular endothelial growth factorChen ERKaiser PKDove Medical Pressarticleneovascular age-related macular degenerationranibizumabport delivery systemvascular endothelial growth factorOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 1349-1355 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	neovascular age-related macular degeneration ranibizumab port delivery system vascular endothelial growth factor Ophthalmology RE1-994
spellingShingle	neovascular age-related macular degeneration ranibizumab port delivery system vascular endothelial growth factor Ophthalmology RE1-994 Chen ER Kaiser PK Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
description	Eric R Chen,1 Peter K Kaiser2 1School of Medicine, Case Western Reserve University, Cleveland, OH, USA; 2Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USACorrespondence: Peter K KaiserCole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3-125, Cleveland, OH 44195, USATel +1 (216) 444-6702Email kaiserp@ccf.orgAbstract: Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults worldwide. The advent of intravitreal neutralization of vascular endothelial growth factor (VEGF) has revolutionized the management of patients with neovascular AMD, but current anti-VEGF therapies carry a high threshold of patient burden. The ranibizumab port delivery system (PDS) is an implanted, refillable reservoir that continuously supplies the anti-VEGF medication ranibizumab directly into the vitreous, eliminating the need for frequent intravitreal injections. It has most recently been evaluated in the Phase II LADDER trial demonstrating the efficacy and safety of the PDS, with Phase III trials currently underway. This review presents both the promise and drawbacks of the PDS in the treatment of AMD from the current literature.Keywords: neovascular age-related macular degeneration, ranibizumab, port delivery system, vascular endothelial growth factor
format	article
author	Chen ER Kaiser PK
author_facet	Chen ER Kaiser PK
author_sort	Chen ER
title	Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
title_short	Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
title_full	Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
title_fullStr	Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
title_full_unstemmed	Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
title_sort	therapeutic potential of the ranibizumab port delivery system in the treatment of amd: evidence to date
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/60b76b3947b14542a819c4a9a24895dd
work_keys_str_mv	AT chener therapeuticpotentialoftheranibizumabportdeliverysysteminthetreatmentofamdevidencetodate AT kaiserpk therapeuticpotentialoftheranibizumabportdeliverysysteminthetreatmentofamdevidencetodate
_version_	1718398664222703616

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date

Ejemplares similares